Biomarker studies from a Phase 1b trial with aromatase inhibitor exemestane showed that the overall response rate was correlated with tumor aromatase expression in postmenopausal women with stage IV non-squamous NSCLC, and the use of exemestane was well-tolerated [144]. The gene discussed is CYP19A1; the disease is neoplasm.